Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision Next revisionBoth sides next revision | ||
| content:valproate [2020/02/17 11:15] – [Main ADRs] icna | content:valproate [2020/02/17 12:52] – [References] icna | ||
|---|---|---|---|
| Line 1: | Line 1: | ||
| ====== Valproate ====== | ====== Valproate ====== | ||
| - | Valproic acid (2-propyl pentanoic acid, 2-propyl valeric acid) is a short-chain branched fatty acid. Prior to the serendipitous discovery of its anti-epileptic activity in 1963, valproic acid was used as an organic solvent. | + | Valproic acid (2-propyl pentanoic acid, 2-propyl valeric acid) is a short-chain branched fatty acid. Prior to the serendipitous discovery of its anti-epileptic activity in 1963, valproic acid was used as an organic solvent[(: |
| ===== Authorised indications ===== | ===== Authorised indications ===== | ||
| UK-SmPC: In the treatment of generalized, | UK-SmPC: In the treatment of generalized, | ||
| Line 125: | Line 125: | ||
| ==== References ==== | ==== References ==== | ||
| ~~REFNOTES~~ | ~~REFNOTES~~ | ||
| - | Source: Panayiotopoulos CP. (2005). The Epilepsies: Seizures, Syndromes and Management. Oxfordshire (UK): Bladon Medical Publishing. | ||